Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Rating of “Moderate Buy” from Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $32.50.

Several analysts recently commented on GLUE shares. JPMorgan Chase & Co. lifted their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Wells Fargo & Company dropped their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Guggenheim lowered their price objective on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th.

Insider Buying and Selling at Monte Rosa Therapeutics

In other news, COO Jennifer Champoux sold 2,175 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $20.00, for a total value of $43,500.00. Following the completion of the sale, the chief operating officer directly owned 62,371 shares in the company, valued at $1,247,420. This represents a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Philip Nickson sold 5,845 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the transaction, the insider directly owned 55,000 shares in the company, valued at approximately $972,950. This represents a 9.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Monte Rosa Therapeutics by 10.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock worth $80,265,000 after buying an additional 481,844 shares during the period. Vanguard Group Inc. grew its stake in shares of Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after acquiring an additional 257,547 shares during the period. State Street Corp increased its holdings in Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after acquiring an additional 1,260,707 shares in the last quarter. AQR Capital Management LLC increased its holdings in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Monte Rosa Therapeutics by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after acquiring an additional 53,278 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE opened at $16.61 on Wednesday. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -11.22 and a beta of 1.60. The business has a 50-day simple moving average of $18.49 and a two-hundred day simple moving average of $18.37. Monte Rosa Therapeutics has a fifty-two week low of $4.12 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The company had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. As a group, research analysts predict that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.